

The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved Stallergenes' half year consolidated financial statement :
Stallergenes has been granted with the market authorization in Germany for its sublingual desensitisation tablet Oralair® Grasses.
Stallergenes launches a phase III clinical trial for Staloral® 300 in China
Stallergenes has started a phase II/III clinical trial on a tablet for desensitisation to mites
In order to pursue its development and to reach its future objectives, Stallergenes is adopting a new logo.
Further profit growth; Sales up 16%;
Profit before R&D up 19%;
Net profit (group share) up 12%;
Acceleration of R&D expenditure
Partnership agreement between STALLERGENES and PROTEIN’EXPERT
The results of a study on children confirmed the efficacy of the ORALAIR® Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.
Signature of an agreement for development and supply of recombinant Bet v 1 (rBet v 1) purified bulk.
2006: Another year of growth